Get started
Work

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.1479
Authors: A.M. Haydon, M. Alamgeer, D. Brungs, F. Collichio, N.I. Khushalani, A.D. Colevas, D. Rischin, R. Kudchadkar, W. Chai-Ho, G. Daniels, J. Lutzky, J.H. Lee, S. Bowyer, M.R. Migden, P. Sheladia, P.K. Bommareddy, S. He, C. Andreu-Vieyra, M.G. Fury, A. Hill
Institutions: The Alfred Hospital, Monash Medical Centre, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Moffitt Cancer Center, Stanford Medicine, Stanford University, Peter MacCallum Cancer Centre, Emory University, Winship Cancer Institute, University of California, Los Angeles, University of California San Diego, Moores Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Chris O’Brien Lifehouse, Sir Charles Gairdner Hospital, Linear Clinical Research, The University of Texas MD Anderson Cancer Center, Replimune Group, Inc. (United States), Regeneron (United States)
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3202380124
FWCI: 0.153
Cites:
Cited by: 2
Related to: 10